
Advancing early detection of pancreatic cancer

Advancing early detection of pancreatic cancer
Be SURE about early detection
PancreaSure is a blood test that measures five different biomarkers to detect the most common form of pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC).
The test is proven to detect pancreatic cancer early – at stage 1 or 2 – when treatments are much more likely to be effective and the changes of survival are much higher.1
Reports will classify a person as “positive” or “negative” with a positive test indicating that pancreatic cancer may be present, and a prompt clinical evaluation is recommended to make a definitive diagnosis.
Would you like more information about ordering the test? Contact us.
1American Cancer Society. Cancer Facts and Figures 2023
The PancreaSure test was validated in a clinical study, CLARITI, in high-risk individuals at risk for familial or hereditary PDAC, the most common type of pancreatic cancer.
The CLARITI study is the largest validation study ever conducted for a pancreatic cancer blood test. Learn more about the CLARITI study here.
Do you have questions about the research behind the PancreaSure test? Contact us.
2 Lucas AL, Simeone DM, Katona BW, et al. Gastroenterology 2025:169(1)S-193
In the CLARITI study of 1,066 blood samples, PancreaSure correctly detected early-stage pancreatic cancer in 78% of people who had it.2
PancreaSure also correctly reported ‘no cancer’ in
94% of people who did not have the disease.2
Genetic risk factors | BRCA1/2, PALB2 – Hereditary breast and ovarian syndrome |
|---|
MLH1, MSH6, MSH2, PMS2, EPCAM – Lynch Syndrome |
FAP, APC – Familial adenomatous polyposis |
STK11/LKB1 – Peutz-Jeghers syndrome |
CDKN2A – Familial atypical multiple mole melanoma |
PRSS1 – Hereditary Pancreatitis |
ATM – Ataxia-telangiectasia |
TP53 – Li-Fraumeni Syndrome |
Other genetic mutations as indicated by your HCP |
PancreaSure is intended for use in people at increased risk of pancreatic cancer due to family history or genetic changes.
PancreaSure may be appropriate if:
Most people will pay $200 or less for the PancreaSure test based on Immunovia’s financial assistance program.
For those that don’t qualify, the cost of the test is $995 but can be reduced to $750 if payment is made within 15 days of receiving the bill.
The chart below is based on federal poverty guidelines and can be used to estimate potential costs based on annual household income and the number of people in the household.
Do you have questions about pricing or financial assistance? Contact us.
If the out-of-pocket cost of the test will be more than $200, an Immunovia representative will call the patient before we process the test.
| Total number of people in household |
Household income | |||
|---|---|---|---|---|
| 1 | Less than $31,300 | $31,301 - $46,950 | $46,951 - $62,600 | More than $62,600 |
| 2 | Less than $42,300 | $42,301 - $63,450 | $63,451 - $84,600 | More than $84,600 |
| 3 | Less than $53,300 | $53,301 - $79,950 | $79,951 - $106,600 | More than $106,600 |
| 4 | Less than $64,300 | $64,301 - $96,450 | $96,451 - $128,600 | More than $128,600 |
| 5 | Less than $75,300 | $75,301 - $112,950 | $112,951 - $150,600 | More than $150,600 |
| 6 | Less than $86,300 | $86,301 - $129,450 | $129,451 - $172,600 | More than $172,600 |
| 7 | Less than $97,300 | $97,301 - $145,950 | $145,951 - $194,600 | More than $194,600 |
| 8 | Less than $108,300 | $108,301 - $162,450 | $162,451 - $216,600 | More than $216,600 |
| PancreaSure Test Cost |
$0 | $100 | $200 | $995 (or $750 with prompt pay discount) |
Have a conversation
Individuals that may be at high risk for pancreatic cancer should discuss their options, including whether the PancreaSure test is appropriate, with their healthcare provider.
Schedule a blood draw
A blood sample is needed for the PancreaSure test. Depending on the provider location, the blood sample can be drawn at the time of appointment or Immunovia can assist in scheduling a follow up appointment for sample collection.
Results Delivered
Once sample is collected, it will be sent to Immunovia’s CLIA and CAP certified laboratory. Results will be shared in a secure, HIPAA compliant portal with the ordering provider within 7-10 business days after receipt of sample. Patients can also request a copy of their results.
If you are a healthcare provider interested in the PancreaSure test, please fill out the Provider Inquiry form and we’ll have a member of our team reach out with next steps for ordering.
If you’re a patient or family member who wants to know more about the PancreaSure test, please fill out the Patient Inquiry form.
If you are interested in Investor Relations, a member of the Media or have a different request and/or interest in PancreaSure or Immunovia, please fill out the Other Inquiry form.
If you are healthcare provider interested in the PancreaSure test, please fill out the Provider Inquiry form and we’ll have a member of our team reach out with next steps for ordering.
If you’re a patient or family member who wants to know more about the PancreaSure test, please fill out the Patient Inquiry form.
If you are interested in Investor Relations, a member of the Media or have a different request and/or interest in PancreaSure or Immunovia, please fill out the Other Inquiry form.
The PancreaSure test is not intended as a stand-alone diagnostic test for pancreatic cancer. Assessment of your clinical information, imaging findings, and family history by a healthcare provider are essential for the appropriate interpretation of PancreaSure test results. As with any test, false positive or false negative results can occur.
For more information, please call (833) 593-9522
PancreaSure is a laboratory-developed test offered through Immunovia’s CAP and CLIA-certified laboratory in Durham, NC.
Clinical Lab Director: Lisa Ford, PhD, HCLD(ABB)
PancreaSure is a trademark of Immunovia, Inc.
© 2025 Immunovia, Inc.